Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
Ronald P. DeMatteo(University of Pennsylvania), Kouros Owzar(Duke University), Martin D. McCarter(University of Colorado Cancer Center), Charles D. Blanke(SWOG Cancer Research Network), Benjamin Tan(Washington University in St. Louis), George D. Demetri(Dana-Farber Cancer Institute), Robert G. Maki(Memorial Sloan Kettering Cancer Center), Karla V. Ballman(Mayo Clinic in Arizona), Murray F. Brennan(Memorial Sloan Kettering Cancer Center), Margaret von Mehren(Temple University Health System), Cristina R. Antonescu(Memorial Sloan Kettering Cancer Center), Jonathan Polikoff, Shreyaskumar Patel(The University of Texas MD Anderson Cancer Center), Peter W. T. Pisters(The University of Texas MD Anderson Cancer Center), Martin E. Blackstein(Mount Sinai Hospital)
Cited by 1,371
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k